Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

ImmunoGen Inc. (IMGN)

4.64   -0.14 (-2.93%) 02-26 16:00
Open: 4.81 Pre. Close: 4.78
High: 5.05 Low: 4.55
Volume: 2,939,970 Market Cap: 808M
Immunogen Inc is a clinical-stage biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.083 - 5.132 5.132 - 5.161
Low: 4.454 - 4.513 4.513 - 4.549
Close: 4.572 - 4.669 4.669 - 4.727

Technical analysis

as of: 2020-02-26 4:29:33 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 7.01     One year: 8.26
Support: Support1: 4.27    Support2: 3.55
Resistance: Resistance1: 6.00    Resistance2: 7.07
Pivot: 5.26
Moving Average: MA(5): 5.10     MA(20): 5.15
MA(100): 4.01     MA(250): 3.11
MACD: MACD(12,26): 0.10     Signal(9): 0.20
Stochastic oscillator: %K(14,3): 13.10     %D(3): 23.22
RSI: RSI(14): 44.14
52-week: High: 7.07  Low: 1.76  Change(%): -1.7
Average Vol(K): 3-Month: 376634  10-Days: 611762

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
IMGN has closed above bottom band by 23.4%. Bollinger Bands are 85.4% wider than normal. The large width of the bands suggest high volatility as compared to IMGN's normal range. The bands have been in this wide range for 7 bars. This is a sign that the current trend might continue.

Headline News

ImmunoGen Beats Expectations and Fuels Optimism for Its Lead Drug Candidate | The Motley Fool
Cost-cutting led to a surprise profit, and the company outlined the path ahead for its pipeline treatment for ovarian cancer.

ImmunoGen (IMGN) Q4 Earnings and Revenues Beat Estimates
ImmunoGen (IMGN) delivered earnings and revenue surprises of 160.00% and 53.43%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 174.22
Shares Float (M) 135.94
% Held by Insiders 1.16
% Held by Institutions 70.57
Shares Short (K) 12550
Shares Short P. Month (K)

Stock Financials

EPS -1.020
Book Value (p.s.) -0.580
PEG Ratio
Profit Margin -296.61
Operating Margin -235.65
Return on Assets (ttm) -25.2
Return on Equity (ttm)
Qtrly Rev. Growth 21.5
Gross Profit (p.s.) -0.695
Sales Per Share
EBITDA (p.s.) -0.662
Qtrly Earnings Growth
Operating Cash Flow (M) -97.09
Levered Free Cash Flow (M) -54.08

Stock Valuations

P/E -4.55
P/E Growth Ratio -0.03
P/BV -8.00
P/S 13.64
P/CF -8.33

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.